Legato Merger Corp III (LEGT) Q1 2026 Earnings Call Transcript

Why It Matters

The results cement Legend as the leading commercial CAR‑T player, expanding access to multiple myeloma patients and delivering a multi‑billion‑dollar revenue runway for investors.

Key Takeaways

• CARVYKTI sales $555M, 66% YoY growth.
• Operating loss cut 75% to $20M negative.
• Manufacturing capacity 10,000 doses, 97% success rate.
• Pipeline includes in vivo and allogeneic CAR‑T programs.
• Target peak CARVYKTI sales >$5 billion with J&J.

Pulse Analysis

Legend Biotech’s Q1 performance underscores the accelerating commercialization of CAR‑T therapies in multiple myeloma. With CARVYKTI now generating $555 million in net trade sales—a 66% increase year‑over‑year—the company has outpaced peers in both revenue growth and margin expansion. The shift from a negative 142% operating margin in early 2023 to a modest negative 6% demonstrates disciplined cost management, while a positive adjusted net income of $2.5 million signals the franchise’s path to profitability. Investors are watching as Legend leverages its cash pile of $949 million to fund further scale‑up.

Manufacturing excellence is a core differentiator for Legend. The firm’s global network now supports 10,000 annual CARVYKTI doses, with a 97% overall product success rate and 99% success for recent batches. This reliability enables rapid expansion into 14 markets and 294 treatment sites, including community hospitals that serve 80% of U.S. patients within 50 miles. Clinical data presented at ASH and Tandem highlight a median progression‑free survival of 50.4 months in heavily pre‑treated patients, reinforcing the therapeutic advantage of earlier‑line use and effective bridging strategies.

Looking ahead, Legend’s pipeline—spanning in‑vivo CAR‑T, allogeneic gamma‑delta CAR‑T, and upcoming IND filings—positions the company to broaden its addressable market beyond multiple myeloma. The strategic partnership with Johnson & Johnson aims to scale CARVYKTI to over $5 billion in peak annual sales, while the company targets full‑year profitability in 2026. This combination of robust cash flow, expanding manufacturing capacity, and a deep clinical portfolio makes Legend a compelling play in the fast‑growing cell‑therapy sector.